ClinicalTrials.gg
Not yet recruitingNCT05452928AMENUpdated Oct 28, 2026

Aciclovir Versus Placebo for HSV-2 Meningitis

A Phase 4 interventional study of Acyclovir 50 MG/ML and Placebo in Herpes Simplex 2 and Meningitis, Viral, sponsored by Jacob Bodilsen. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Jacob Bodilsen · Phase 4, Interventional, and Treatment

How we know

Updated Oct 28, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Sex
All
01

Study summary

To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation

02

Conditions studied

  • Herpes Simplex 2
  • Meningitis, Viral

Browse trials for

Keywords

  • meningitis
  • HSV-2
  • Herpes simplex 2
  • viral meningitis
  • aseptic meningitis
  • acyclovir
  • valacyclovir
  • aciclovir
  • valaciclovir
03

In context

Meningitis

268 studies on the registry are indexed under Meningitis; 28 are open to participants now.

This study's planned enrollment of 150 is below the median of 260 across 185 interventional studies indexed under Meningitis.

Browse Meningitis studies →

Lead sponsor

Jacob Bodilsen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years of age admitted on suspicion of viral meningitis defined as:

    1. A clinical presentation consistent with viral meningitis (e.g. headache, nuchal rigidity, photophobia, or fever) AND
    2. Cerebrospinal fluid (CSF) pleocytosis (>4 leukocytes x 106/L) AND
    3. HSV-2 positive by PCR of the CSF
    4. Glasgow Coma Scale score of 15 AND
    5. Ability to absorb oral medications

Exclusion criteria

Exclusion Criteria:

  • Patients fulfilling any of the following criteria will be excluded:

    1. Encephalitis as defined by the International Encephalitis Consortium if diagnosed during standard care (see Glossary)20
    2. Transverse myelitis as defined by the Transverse Myelitis Consortium Working Group if diagnosed during standard care (see Glossary)21
    3. Severe immuno-compromise defined as an ongoing need for biological- or chemotherapy (e.g. natalizumab), prednisolone >20 mg/day for ≥14 days, uncontrolled /AIDS (see glossary), haematological , and organ transplant recipients14,18,22
    4. Moderate to severe concomitant genital herpes requiring systemic aciclovir
    5. Pregnancy (proven by positive urine or plasma human chorionic gonadotropin test in fertile women)
    6. Hepatic impairment ( or alanine aminotransferase levels >5 times the )
    7. Impaired renal function (estimated \<25 mL/min)
    8. Intolerance to (val)aciclovir
    9. Probenecid treatment
    10. Systemic antiviral therapy with an antiherpetic effect for >24 hours
    11. Previous enrolment into this trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Active arm

    Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).

    Drug: Acyclovir 50 MG/ML

  • Placebo comparator
    Placebo

    Randomisation to 7 days of IV and/or oral placebo.

    Drug: Placebo

Interventions

  • DrugAcyclovir 50 MG/ML

    Drug page: AcyclovirStudies of AcyclovirAcyclovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.

    Also known as: Valacyclovir

  • DrugPlacebo

    Placebo either in IV formulation or as tablets identical to valacyclovir tablets.

06

What researchers measure

Primary outcomes

  1. Primary endpoint (proportion with a Total Morbidity Score)

    The proportion with a Total Morbidity Score (TMS) \>6 is considered treatment failure. The score is a sum of scores for headache (range 0 to 6), nuchal rigidity (range 0 to 4), photophobia (range 0 to 4), myalgia (range 0 to 4), fever (range 0 to 4), nausea (range 0 to 4). The score thus ranges from 0 to 21 with higher scores indicating more severe symptoms.

    Time frame: 7 days since randomisation

Secondary outcomes

  1. Secondary endpoint 1 (Proportion of patients with ≤50% reduction of Total Morbidity Score)

    Proportion of patients with ≤50% reduction of Total Morbidity Score since randomisation. Please see characterization of score under primary endpoint.

    Time frame: 7 days since randomisation

  2. Secondary endpoint 2 Extended Glasgow outcome scale score

    Extended Glasgow outcome scale score. Range 1 to 8 with higher scores indicating better outcome.

    Time frame: 7 days, 3 months, and 12 months since randomisation

  3. Secondary endpoint 3 All-cause mortality

    All-cause mortality

    Time frame: 7 days, 3 months, and 12 months since randomisation

  4. Secondary endpoint 4 EQ-5D-5L

    EQ-5D-5L. Comprises 5 questions with an ordinal scale from 1 to 5 with higher scores indicating more morbidity. Finally, a visual analog score is filled ranging from 0 to 100 with higher scores indicating better health.

    Time frame: 7 days, 3 months, and 12 months since randomisation

  5. Secondary endpoint 5 Mental Fatigue Scale

    Mental Fatigue Scale. Comprises 14 questions with scores from 0 to 3 with higher values suggesting more morbidity. A combined score \>10.5 usually suggests mental fatigue problems.

    Time frame: 7 days, 3 months, and 12 months since randomisation

  6. Secondary endpoint 6 (SF-36)

    Short Form Health Survey 36 (SF-36). Scores eight different domains from 0 to 100 with higher values indicating no disability.

    Time frame: 7 days, 3 months, and 12 months since randomisation

  7. Secondary outcome 7 neurological deficit

    Any new neurological deficit reported by patient or observed during clinical examination

    Time frame: 7 days, 3 months, and 12 months since randomisation

  8. Secondary outcome 8 Completion of assigned treatment

    Completion of assigned treatment (active or placebo) assessed by administered intravenous or oral treatment as signed off by nurses in hospitalized patients and pill counts for patients discharged with oral study drug.

    Time frame: 7 days since randomisation

  9. Secondary outcome 9 complications

    Peripheral venous line associated complications (i.e. catheter-associated infection, thrombosis, or haemorrhage).

    Time frame: 7 days since randomisation

  10. Secondary outcome 10Severe adverse events

    Severe adverse events, i.e. incident treatment-emergent serious adverse events.

    Time frame: 7 days since randomisation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Data will be deposited at Mendeley Data (https://data.mendeley.com/).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning six months and ending three years after publication, an anonymized dataset can be shared.

Access criteria: Qualified researchers who provide a methodologically sound proposal.

Data sharing details ↗ · data.mendeley.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Dec 2031, 59 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Jun 2026 → Jan 2027, primary completion Jun 2028 → Dec 2031 and completion Jun 2029 → Dec 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2022
First posted
Jul 12, 2022
StartEst.
Jan 1, 2027was Jun 2026
Primary completionEst.
Dec 31, 2031was Jun 2028
CompletionEst.
Dec 31, 2032was Jun 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jan 1, 2027
Oct 28, 2026
Primary completion
Jun 1, 2028→Dec 31, 2031
Oct 28, 2026
Study completion
Jun 1, 2029→Dec 31, 2032
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date Jun 1, 2026→Jan 1, 2027
    Primary completion Jun 1, 2028→Dec 31, 2031
    Study completion Jun 1, 2029→Dec 31, 2032
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05452928
Lead sponsor
Jacob Bodilsen
Responsible party
Jacob Bodilsen (Sponsor-investigator, Aalborg University Hospital) — Sponsor-investigator
First posted
Jul 12, 2022
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2031 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 28, 2026

Study contacts

Jacob Bodilsen, MD
Contact
jacob.bodilsen@rn.dk
004597663920
Henrik Nielsen, Professor
Contact
henrik.nielsen@rn.dk
004597663920

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acyclovir

Start the discussion